Hereditary Multiple Osteochondromas and Related Disorders Panel
Use
This test is intended for individuals with a clinical or suspected diagnosis of Hereditary Multiple Osteochondromas (HMO), those with multiple or solitary osteochondroma(s), and individuals, particularly children, with a family member presumed to have Hereditary Multiple Osteochondromas who have not undergone previous genetic testing. It aims to identify genetic variants associated with these disorders to aid in diagnosis and guide management plans.
Special Instructions
The test uses Next Generation Sequencing with CNV analysis on either an Exome or Genome Platform. It requires a completed online or paper test requisition form and labeled specimen for order initiation.
Limitations
The test is validated under CAP and CLIA regulations but is not FDA approved. Results are influenced by the quality of clinical information provided. Interpretation directly correlates with detailed clinical notes and family medical history included in the order.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
14-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided